



## ASX Release

# Change to Exercise Price of Options

Melbourne, Australia - (July, 20 2016) – Clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX) announces that following completion of the recent 1 for 3 pro-rata non-renounceable entitlement offer, and in accordance with the Prescient Option terms and listing rule 3.11.2, the Company advises that, as a consequence of the Entitlement Offer, the exercise price of certain options over unissued ordinary shares in the Company will change on 27 July 2016 as set out in the table below.

Unlisted Options	Current exercise price	New exercise price
4,385,000	\$0.10	\$0.096
500,000	\$0.14	\$0.136
300,000	\$0.092	\$0.088
200,000	\$0.06	\$0.056
700,000	\$0.085	\$0.081

## ENDS

### About Prescient Therapeutics Limited (PTX)

PTX is a clinical stage oncology company developing novel compounds that show promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

PTX's lead drug candidate PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound is now the focus of three current clinical trials.

The first trial is a Phase Ib/II trial evaluating PTX-200 as a new therapy for relapse and refractory Acute Myeloid Leukemia, being conducted at Florida's H. Lee Moffitt Cancer Center (Moffitt) and Yale Cancer Center (Yale) in New Haven, Connecticut under the leadership of Principal Investigator Professor Jeffrey Lancet, MD.

PTX is also conducting a Phase Ib/II study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York and the Moffitt. The third trial is a Phase Ib/II trial of PTX-200 in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at the Moffitt.



PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase I trial in advanced solid tumors.

**Further enquiries:**

Melanie Leydin  
Company Secretary  
+61 3 9692 7222